STA®-Rivaroxaban Calibrator & STA®-Rivaroxaban Control*

 Zurück zu:Neue Produkte

Rivaroxaban is a new oral anticoagulant developed by Bayer HealthCare and sold under the trade name Xarelto®. It is a direct factor Xa inhibitor approved for the prevention of VTE after hip or knee replacement surgery in more than 80 countries (except US). Rivaroxaban is expected to be approved for other indications like stroke prevention in patients with atrial fibrillation in the near future. This makes rivaroxaban a future major player in the anticoagulants world.
Anticoagulant Line

STA®-Rivaroxaban Calibrator &Control is a new solution for the determination of rivaroxaban concentration when required.
Including rivaroxaban calibrators and controls, this solution can be used with two methods for different clinical needs and laboratory requirements:

  • PT derived method (STA®-Néoplastine® CI Plus), a global test available everywhere and cost effective, for screening purposes
  • Anti-Xa method (STA®-Liquid Anti-Xa) insensitive to analytical and biological variables, with a wide working range

Results are expressed in ng/mL of rivaroxaban [1,2].

Reagents are offered with all the standard guarantees:

  • barcoded reagents for optimal ease of handling and traceability
  • results available in a few minutes only, adapted to STAT samples requirement
  • fully automated on the STA® line, with dedicated test setups.

1. SAMAMA M.M. et al., Rivaroxaban calibrator and control sets measuring rivaroxaban plasma concentrations using prothrombin time, ICT, Milan, Italy, poster, 2010.
2. SAMAMA M.M. et al., Evaluation of the anti-factor Xa chromogenic assay for measuring rivaroxaban plasma concentrations using calibrators and controls, ASH, 5071 b JN04, Abstract, 2010.

Available now.

* For Research Use Only